ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sino Biopharmaceutical and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Sino BiopharmaceuticalBristol-Myers Squibb
studies on the registry4712,184
open to participants now163155
phase 3 studies under way4682
reach primary completion within a year5767
programswith a study of their own in two years97+19 named only57+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSino BiopharmaceuticalBristol-Myers Squibb
Phase 1

Sino Biopharmaceutical: 37 of its 97 programs at phase 1

  1. TQF3250phase 1
  2. TQB2101phase 1
  3. 1200mg of tqb2928 injectionphase 1
  4. Anecatibin Fumarate Capsulesphase 1
  5. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1

and 32 more — sign in to see them all

38%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%
Phase 2

Sino Biopharmaceutical: 31 of its 97 programs at phase 2

  1. JAK2 Inhibitor TQ05105phase 2
  2. TQB2922phase 2
  3. TRD205phase 2
  4. BTK Inhibitor TQB3702phase 2
  5. TQB6411phase 2

and 26 more — sign in to see them all

32%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%
Phase 3

Sino Biopharmaceutical: 26 of its 97 programs at phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. NTQ5082phase 3
  5. culmerciclibphase 3

and 21 more — sign in to see them all

27%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies

Sino Biopharmaceutical: 3 of its 97 programs at approved, new studies

  1. catequentinib hydrochlorideapproved, new study
  2. Adalimumabapproved, new study
  3. TyboWe® Adalimumab Injectionapproved, new study
3%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sino Biopharmaceutical37 readouts · 10 phase 3

Sino Biopharmaceutical, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868phase 3 · Nov 0 · NCT06767813
  2. NTQ5082phase 3 · Nov 0 · NCT07177859
  3. TQB2252phase 1 · Nov 0 · NCT06649656
  4. TQH2722phase 3 · Nov 0 · NCT07398859

Sino Biopharmaceutical, Dec ’26: 14 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-HER2 Bispecific Antibody TQB2930phase 3 · Dec 0 · NCT06202261
  2. BET Inhibitor TQB3617phase 2 · Dec 0 · NCT06122831
  3. BTK Inhibitor TQB3702phase 2 · Dec 0 · NCT06859931
  4. catequentinib hydrochlorideapproved, new study · Dec 0 · NCT04344158
  5. culmerciclibphase 3 · Dec 0 · NCT05780567

and 9 more — sign in to see them all

Sino Biopharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3 · Jan 0 · NCT06561607
  2. vilzemetkibphase 3 · Jan 0 · NCT06860971

Sino Biopharmaceutical, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB6411phase 2 · Feb 0 · NCT07367516
  2. TQC3721phase 3 · Feb 0 · NCT07464587

Sino Biopharmaceutical, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anecatibin Fumarate Capsulesphase 1 · Mar 0 · NCT07538973
  2. TQB3473phase 3 · Mar 0 · NCT06900920
  3. TQC2938phase 2 · Mar 17 · NCT06789289

Sino Biopharmaceutical, Apr ’27: 2 programs whose next study reaches primary completion

  1. NTQ6179phase 1 · Apr 0 · NCT07909837
  2. TQB3201phase 2 · Apr 0 · NCT07172126

Sino Biopharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. NTB003phase 2 · May 31 · NCT07462130
·

Sino Biopharmaceutical, Jul ’27: 2 programs whose next study reaches primary completion

  1. TQD3524phase 2 · Jul 0 · NCT07512596
  2. TQH3906phase 3 · Jul 0 · NCT06754891

Sino Biopharmaceutical, Aug ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. TQB2916phase 2 · Aug 0 · NCT06962267
  2. TQB6426phase 1 · Aug 0 · NCT07730190
  3. trifluridine tipiracil drug combinationphase 3 · Aug 0 · NCT07483684
  4. LM-168phase 2 · Aug 1 · NCT06868199
  5. KYLO-0603phase 2 · Aug 15 · NCT07878091
·

Sino Biopharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3 · Oct 0 · NCT07179679
  2. Anti-CD137/PD-L1 Bispecific Antibody FS222phase 1 · Oct 30 · NCT04740424
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sino Biopharmaceutical

New programs 3

  • NTQ6179phase 1 · first study · Oct 20 · Acromegaly
  • KYLO-0603phase 2 · first study · Sep 24 · Non-alcoholic Fatty Liver Disease
  • TQF6422phase 1 · first study · Aug 26 · Obesity

Reached a new phase 1

  • TQA3605phase 3 · Aug 28 · Hepatitis B, Chronic

Study stopped 0

None

Primary completion later 4

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 29 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionSino BiopharmaceuticalBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungboth · compare here

Sino Biopharmaceutical in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102phase 3
  2. benmelstobartphase 3
  3. penpulimabphase 3
  4. vilzemetkibphase 3
  5. FHND-9041phase 3

and 5 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Multiple Myelomaboth · compare here

Sino Biopharmaceutical in Multiple Myeloma: 3 programs

  1. Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934phase 3
  2. FHND6091phase 1
  3. TQB2029phase 1

Their studies: Sino Biopharmaceutical’s studies of Multiple Myeloma in search

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Colorectal Neoplasmsboth · compare here

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

Sino Biopharmaceutical in Carcinoma, Hepatocellular: 3 programs

  1. penpulimabphase 3
  2. tislelizumabphase 2
  3. catequentinib hydrochlorideapproved, new study

Their studies: Sino Biopharmaceutical’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Neoplasmsboth · compare here

Sino Biopharmaceutical in Neoplasms: 2 programs

  1. LM-364phase 2
  2. LM-350phase 2

Their studies: Sino Biopharmaceutical’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Sino Biopharmaceutical in Pulmonary Disease, Chronic Obstructive: 6 programs

  1. TQC2731phase 3
  2. TQC3721phase 3
  3. TQC2938phase 2
  4. TQC3927phase 2
  5. TQC3302phase 1

and 1 more — sign in to see them all

Their studies: Sino Biopharmaceutical’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

Small Cell Lung Carcinomaboth · compare here

Sino Biopharmaceutical in Small Cell Lung Carcinoma: 2 programs

  1. benmelstobartphase 3
  2. trifluridine tipiracil drug combinationphase 3

Their studies: Sino Biopharmaceutical’s studies of Small Cell Lung Carcinoma in search

Bristol-Myers Squibb in Small Cell Lung Carcinoma: 5 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. atigotatugphase 3
  4. BMS-986525phase 2
  5. atigotatugphase 2

Their studies: Bristol-Myers Squibb’s studies of Small Cell Lung Carcinoma in search

Alzheimer Diseaseboth · compare here

Sino Biopharmaceutical in Alzheimer Disease: 1 program

  1. Semaglutidephase 3

Their studies: Sino Biopharmaceutical’s studies of Alzheimer Disease in search

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

Lupus Erythematosus, Systemicboth · compare here

Sino Biopharmaceutical in Lupus Erythematosus, Systemic: 2 programs

  1. TQH3906phase 3
  2. BTK Inhibitor TQB3702phase 2

Their studies: Sino Biopharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Follicularboth · compare here

Sino Biopharmaceutical in Lymphoma, Follicular: 2 programs

  1. TQB2825phase 3
  2. JAK2 Inhibitor TQ05105phase 2

Their studies: Sino Biopharmaceutical’s studies of Lymphoma, Follicular in search

Bristol-Myers Squibb in Lymphoma, Follicular: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Follicular in search

Pancreatic Neoplasmsboth · compare here

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

Show all 29

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sino Biopharmaceutical 70 of 97 · Bristol-Myers Squibb 32 of 57 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sino Biopharmaceutical: 19, Bristol-Myers Squibb: 9).